drugset / Trial / NCT02135445
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
Timeline
- Start
- 2014-06
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Relugolix | Small molecule | 120 mg | Oral |